Investors of Reckitt Benckiser Group PLC urged to get involved in securities fraud lawsuit
In recent news, the Rosen Law Firm, a prominent global firm advocating for investor rights, is drawing attention to an urgent opportunity for purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs). According to the investment firm, individuals who acquired these shares between January 13, 2021, and July 28, 2024, are eligible to join a class action lawsuit due to an alleged securities fraud. This lawsuit aims to hold Reckitt Benckiser accountable for failing to adequately inform investors about critical risks associated with its products.
The lead plaintiff deadline is set for August 4, 2025, presenting a crucial time frame for affected investors to assert their rights. Rosen Law Firm outlines that by joining this class action, investors might claim compensation without incurring any out-of-pocket costs, as they operate on a contingency fee basis. Interested investors can easily initiate engagement by visiting the firm's website or by directly contacting their legal team through a toll-free number or email.
This ongoing class action contends that Reckitt Benckiser misled stakeholders regarding the safety of its infant formula product, Enfamil. The lawsuit alleges that during the specified class period, the company neglected to warn both consumers and investors about the heightened risk of necrotizing enterocolitis (NEC) in preterm infants linked to the use of this formula. Such omissions, according to the legal complaint, rendered positive statements made by the company's officials about Reckitt's operational health and future prospects materially misleading and false.
As details of these claims came to light, it is argued that investors faced significant financial damage, highlighting the serious implications of the matter. The Rosen Law Firm emphasizes the importance of selecting attorneys with a proven history in effectively managing securities class actions. Unlike some firms that merely act as conduits or referrals to litigation, Rosen Law Firm boasts extensive experience and notable achievements in this field.
Notably, they secured the largest-ever settlement against a Chinese company for securities-related issues and ranked highly in multiple years for their successful settlements on behalf of investors. Their founding partner, Laurence Rosen, has been recognized as a significant figure within the plaintiffs’ bar, showcasing the firm’s commitment to fighting for investor rights.
For investors considering taking part in this class action, joining is straightforward: fill out the submission form on the Rosen Law Firm website or reach out via telephone. However, until a class is certified, the firm notes that you are not officially represented unless you retain counsel. Therefore, interested parties should act promptly to secure their place and determine the best course of action.
Keeping abreast of developments in the class action through social media and legal updates from firms such as Rosen is also advisable. Investors are encouraged to stay informed about their positions and the potential outcomes of participating in this legal challenge. As the case unfolds, it will be interesting to see how Reckitt Benckiser will respond to these allegations and what this means for its market position and shareholders moving forward.
The lead plaintiff deadline is set for August 4, 2025, presenting a crucial time frame for affected investors to assert their rights. Rosen Law Firm outlines that by joining this class action, investors might claim compensation without incurring any out-of-pocket costs, as they operate on a contingency fee basis. Interested investors can easily initiate engagement by visiting the firm's website or by directly contacting their legal team through a toll-free number or email.
This ongoing class action contends that Reckitt Benckiser misled stakeholders regarding the safety of its infant formula product, Enfamil. The lawsuit alleges that during the specified class period, the company neglected to warn both consumers and investors about the heightened risk of necrotizing enterocolitis (NEC) in preterm infants linked to the use of this formula. Such omissions, according to the legal complaint, rendered positive statements made by the company's officials about Reckitt's operational health and future prospects materially misleading and false.
As details of these claims came to light, it is argued that investors faced significant financial damage, highlighting the serious implications of the matter. The Rosen Law Firm emphasizes the importance of selecting attorneys with a proven history in effectively managing securities class actions. Unlike some firms that merely act as conduits or referrals to litigation, Rosen Law Firm boasts extensive experience and notable achievements in this field.
Notably, they secured the largest-ever settlement against a Chinese company for securities-related issues and ranked highly in multiple years for their successful settlements on behalf of investors. Their founding partner, Laurence Rosen, has been recognized as a significant figure within the plaintiffs’ bar, showcasing the firm’s commitment to fighting for investor rights.
For investors considering taking part in this class action, joining is straightforward: fill out the submission form on the Rosen Law Firm website or reach out via telephone. However, until a class is certified, the firm notes that you are not officially represented unless you retain counsel. Therefore, interested parties should act promptly to secure their place and determine the best course of action.
Keeping abreast of developments in the class action through social media and legal updates from firms such as Rosen is also advisable. Investors are encouraged to stay informed about their positions and the potential outcomes of participating in this legal challenge. As the case unfolds, it will be interesting to see how Reckitt Benckiser will respond to these allegations and what this means for its market position and shareholders moving forward.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.